Thermo Fisher May Test the Old Highs
Thermo Fisher Scientific was among the few Wall St firms to increase its share price this week against the falling S&P 500 barometer. The life science and clinical research firm generated $5.37 per share in Q2 and, compared to average analyst bets on $5.12 per share, and thus added 4.07% to more than $200 billion of its market value on July 24, while also raising its profit outlook for the rest of the year. The company's management now foresees annual earnings within a range between $21.29 and $22.07 per share, compared with its own previous estimates of $21.14 to $22.02 per share.
Thermo Fisher is a supplier of various analytical instruments for diagnostics, medicine laboratories, and so is part of the so-called "big pharma" industry. Not all the companies in this segment but many of them are feeling well and may be considered as a reasonable alternative to IT investments during the partial rotation in stock market. It is sufficient to recall an ever-trending Eli Lilly and climbing Merck. TMO's share price recently re-tested the technical support at $530, so that the following rebound may be a sign of targeting at an attempt to break through a $600 to $615 area that was cupping the further upside move since the spring of 2022, while keeping its $672.34 (January 2021) all-time high in mind.
The company's total sales were at $10.54 billion, almost in line with estimates of $10.51 billion, still below than $10.69 billion in Q2 2023, yet its major laboratory and biopharma services segment for clinical trials came out at $5.76 billion, well above consensus expectations of $5.48 billion. Its CEO Marc N. Casper who first joined the company in 2001 was talking much about strategic growth initiatives and the efficiency of its Practical Process Improvement (PPI) business system during the conference call. Most investors liked his commitment to innovations and high-impact products like the Thermo Scientific™ Stellar™ mass spectrometer, new editions of the Thermo Scientific Orbitrap Ascend Tribrid™ mass spectrometer, bioprocessing containers and ENERGY STAR-certified freezers.
Only a day ago, the company's rival Danaher witnessed "positive momentum" for products and services used to develop biological drugs to mark an improving background for the segment. The recent acquisition of Olink, which is a provider of next-generation proteomic solutions (related to the entire set of proteins in cells and tissues), may also help Thermo Fisher's leadership.
Disclaimer:
The comments, insights, and reviews posted in this section are solely the opinions and perspectives of authors and do not represent the views or endorsements of RHC Investments or its administrators, except if explicitly indicated. RHC Investments provides a platform for users to share their thoughts on financial market news, investing strategies, and related topics. However, we do not guarantee the accuracy, completeness, or reliability of any user-generated content.
Investment Risks and Advice:
Please be aware that all investment decisions involve risks, and the information shared on metadoro.com should not be considered as financial advice. Always conduct thorough research, seek professional advice, and exercise caution when making investment decisions.
Moderation and Monitoring:
While we strive to maintain a respectful and informative environment, we cannot endorse or verify the accuracy of all user-generated content. We reserve the right to moderate, edit, or remove any comments or posts that violate our community guidelines, infringe on intellectual property rights, or contain harmful content.
Content Ownership:
By submitting content to metadoro.com, users grant RHC Investments a non-exclusive, royalty-free license to use, display, and distribute the content. Users are responsible for ensuring they have the necessary rights to share the content they post.
Community Guidelines:
To maintain a positive and respectful community, users are expected to adhere to the community guidelines of Metadoro. Any content that is misleading, offensive, or violates applicable laws and regulations will be subject to moderation or removal.
Changes to Disclaimer:
We reserve the right to update, modify, or amend this disclaimer at any time. Users are encouraged to review this disclaimer periodically to stay informed about any changes.